Oricell Therapeutics: Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), a China-based innovative pharmaceutical company committed to the development of tumor cellular

Related Keywords

New York ,United States ,Qatar ,Shanghai ,China ,Hong Kong ,Suzhou ,Jiangsu ,Xiamen ,Fujian ,Boston ,Massachusetts ,Beijing ,Qiming ,Sichuan ,London ,City Of ,United Kingdom ,State Of Qatar ,American ,Dennis Riedl ,Broderick Wong ,Helen Yang ,American Society Of Clinical Oncology ,Xiamencd Corporation ,Prnewswire Oricell Therapeutics Co Ltd ,Qatar Investment Authority ,European Hematology Association ,Qiming Venture Partners ,Clinical Oncology ,Annual Meeting ,Refractory Multiple Myeloma ,Lancet Haematology ,Managing Partner ,Chief Investment Officer ,Investment Authority ,San Francisco Bay ,Xiamencd Corporation Limited ,Oricell Therapeutics ,Oricell ,Herapeutics ,Loses ,Series ,Financing ,Xpand ,Development ,Products ,